Evaluating the Feasibility, Acceptance, and Beneficial Effects of Online Occupational Therapy for Post-COVID-19 Condition: Protocol for a Randomized Controlled Trial (ErgoLoCo Study).

COVID-19 RCT SARS-CoV-2 acceptability cognitive deficits controlled trials digital health digital intervention effectiveness feasibility internet based long Covid occupational therapy online therapy online treatment pandemic post COVID-19 condition prerecorded randomized controlled trial video

Journal

JMIR research protocols
ISSN: 1929-0748
Titre abrégé: JMIR Res Protoc
Pays: Canada
ID NLM: 101599504

Informations de publication

Date de publication:
13 May 2024
Historique:
received: 26 06 2023
accepted: 21 02 2024
revised: 07 02 2024
medline: 13 5 2024
pubmed: 13 5 2024
entrez: 13 5 2024
Statut: epublish

Résumé

Post-COVID-19 syndrome (PCS; also known as "long COVID") is a relatively novel disease comprising physical, psychological, and cognitive complaints persisting several weeks to months after acute infection with SARS-CoV-2. Approximately 10% of patients with COVID-19 are affected by long-term symptoms. However, effective treatment strategies are lacking. The ErgoLoCo (Occupational Therapy [Ergotherapie] for Long COVID) study was designed to develop and evaluate a novel occupational therapy (OT) concept of online delivery of therapy for long COVID. The primary study objective is to assess the feasibility of the online OT intervention in PCS. Secondary aims include the evaluation of online OT concerning cognitive problems, occupational performance, and social participation. This randomized controlled interventional pilot study involves parallel mixed methods process analyses and a realist evaluation approach. A total of 80 clients with PCS aged at least 16 years will be recruited into two interventional groups. The control cohort (watch and wait) comprises 80 clients with long COVID. Treatment is provided through teletherapy (n=40) or delivery of prerecorded videos (n=40) using the same standardized OT concept twice weekly over 12 weeks. Analyses of quantitative questionnaires and qualitative interviews based on the theoretical framework of acceptability will be performed to assess feasibility. Focus group meetings will be used to assess how acceptable and helpful the intervention was to the participating occupational therapists. Standardized tests will be used to assess the initial efficacy of the intervention on neurocognitive performance; limitations in mobility, self-care, and everyday activities; pain; disabilities; quality of life (QoL); social participation; and anxiety and depression in PCS, and the possible effects of online OT on these complaints. The German Ministry of Education and Research provided funding for this research in March 2022. Data collection took place from October 2022 to August 31, 2023. Data analysis will be completed by the end of April 2024. We anticipate publishing the results in the fall of 2024. Despite the enormous clinical need, effective and scalable treatment options for OT clients who have PCS remain scarce. The ErgoLoCo study will assess whether online-delivered OT is a feasible treatment approach in PCS. Furthermore, this study will assess the effect of the intervention on cognitive symptoms, QoL, and occupational performance and participation in everyday life. Particular emphasis will be placed on the experiences of clients and occupational therapists with digitally delivered OT. This study will pave the way for novel and effective treatment strategies in PCS. German Clinical Trial Registry DRKS00029990; https://drks.de/search/de/trial/DRKS00029990. PRR1-10.2196/50230.

Sections du résumé

BACKGROUND BACKGROUND
Post-COVID-19 syndrome (PCS; also known as "long COVID") is a relatively novel disease comprising physical, psychological, and cognitive complaints persisting several weeks to months after acute infection with SARS-CoV-2. Approximately 10% of patients with COVID-19 are affected by long-term symptoms. However, effective treatment strategies are lacking. The ErgoLoCo (Occupational Therapy [Ergotherapie] for Long COVID) study was designed to develop and evaluate a novel occupational therapy (OT) concept of online delivery of therapy for long COVID.
OBJECTIVE OBJECTIVE
The primary study objective is to assess the feasibility of the online OT intervention in PCS. Secondary aims include the evaluation of online OT concerning cognitive problems, occupational performance, and social participation.
METHODS METHODS
This randomized controlled interventional pilot study involves parallel mixed methods process analyses and a realist evaluation approach. A total of 80 clients with PCS aged at least 16 years will be recruited into two interventional groups. The control cohort (watch and wait) comprises 80 clients with long COVID. Treatment is provided through teletherapy (n=40) or delivery of prerecorded videos (n=40) using the same standardized OT concept twice weekly over 12 weeks. Analyses of quantitative questionnaires and qualitative interviews based on the theoretical framework of acceptability will be performed to assess feasibility. Focus group meetings will be used to assess how acceptable and helpful the intervention was to the participating occupational therapists. Standardized tests will be used to assess the initial efficacy of the intervention on neurocognitive performance; limitations in mobility, self-care, and everyday activities; pain; disabilities; quality of life (QoL); social participation; and anxiety and depression in PCS, and the possible effects of online OT on these complaints.
RESULTS RESULTS
The German Ministry of Education and Research provided funding for this research in March 2022. Data collection took place from October 2022 to August 31, 2023. Data analysis will be completed by the end of April 2024. We anticipate publishing the results in the fall of 2024.
CONCLUSIONS CONCLUSIONS
Despite the enormous clinical need, effective and scalable treatment options for OT clients who have PCS remain scarce. The ErgoLoCo study will assess whether online-delivered OT is a feasible treatment approach in PCS. Furthermore, this study will assess the effect of the intervention on cognitive symptoms, QoL, and occupational performance and participation in everyday life. Particular emphasis will be placed on the experiences of clients and occupational therapists with digitally delivered OT. This study will pave the way for novel and effective treatment strategies in PCS.
TRIAL REGISTRATION BACKGROUND
German Clinical Trial Registry DRKS00029990; https://drks.de/search/de/trial/DRKS00029990.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) UNASSIGNED
PRR1-10.2196/50230.

Identifiants

pubmed: 38739435
pii: v13i1e50230
doi: 10.2196/50230
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Randomized Controlled Trial Clinical Trial Protocol

Langues

eng

Sous-ensembles de citation

IM

Pagination

e50230

Informations de copyright

©Christina Müllenmeister, Andrea Stoelting, Dominik Schröder, Tim Schmachtenberg, Simon Ritter, Iman El-Sayed, Sandra Steffens, Frank Klawonn, Sandra Klawitter, Stefanie Homann, Marie Mikuteit, Christoph Berg, Georg Behrens, Eva Hummers, Aisha Cook, Frank Müller, Alexandra Dopfer-Jablonka, Christine Happle. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 13.05.2024.

Auteurs

Christina Müllenmeister (C)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.

Andrea Stoelting (A)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.

Dominik Schröder (D)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.

Tim Schmachtenberg (T)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.
Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.

Simon Ritter (S)

Department of Pediatric Pulmology, Allergology and Neoantology, Hannover Medical School, Hannover, Germany.
RESIST Cluster of Excellence, Hannover, Germany.

Iman El-Sayed (I)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.

Sandra Steffens (S)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.

Frank Klawonn (F)

Department of Computer Science, Ostfalia University of Applied Sciences, Wolfenbuettel, Germany.
Biostatistics Research Group, Helmholtz Centre for Infection Research, Braunschweig, Germany.

Sandra Klawitter (S)

Department of Computer Science, Ostfalia University of Applied Sciences, Wolfenbuettel, Germany.

Stefanie Homann (S)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.

Marie Mikuteit (M)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
Department of Dermatology, Hannover Medical School, Hannover, Germany.

Christoph Berg (C)

FOM University of Applied Sciences for Economics and Management, Hannover, Germany.

Georg Behrens (G)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
German Center for Infection Research, partner site Hannover-Brunswick, Hannover, Germany.

Eva Hummers (E)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.

Aisha Cook (A)

Timmcook Occupational Therapy Center, Hannover, Germany.

Frank Müller (F)

Department of General Practice, University Medical Center Goettingen, Goettingen, Germany.
Department of Family Medicine, Michigan State University, Grand Rapids, MI, United States.

Alexandra Dopfer-Jablonka (A)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
RESIST Cluster of Excellence, Hannover, Germany.

Christine Happle (C)

Department of Rheumatology and Immunology, Hannover Medical School, Hannover, Germany.
RESIST Cluster of Excellence, Hannover, Germany.
Biomedical Research in End-stage and Obstructive Lung Disease Hannover, German Center for Lung Research, Hannover, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH